Integrum AB (publ) (INTEG_B) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to today's episode of Integrum, which will be reporting the second quarter of 2025. After the presentation, we will have a Q&A session. If you have any questions for the company, you can send them in the form to the right. With that said, I'll hand over to Martin and Louise. Thank you, Ludvig, and welcome to our second quarter of the 25-26 business year. A short introduction to the company. Integrum is a pharmaceutical company. We are Swedish and we operate in Gothenburg. We have at least two markets in Europe and our primary market in the USA, where we also have a sales and marketing office with about 10 people. We have been active since 1998, but have been commercial a little more since 2020. Vi förändrar amputerade människors liv. Freedom and mobility for every person är vår ambition. Det är det som leder vårt arbete framåt. Vi opererar i en marknad som är stor. Cirka 3,9 miljoner människor i Europa och USA är amputerade. Varav ungefär 350 000 amputerade tillkommer i Europa. Our delivery in our system consists of an implant, an abatement that is a pillar of the implant that meets an axis that is our Connector device. And our patients get individual prostheses all under the armpits. That is our Opera Implant System and that is our product that we market for. We create a big change for our patients. We take an amputated patient from a Either a wheelchair or a limited life situation, where we create a life for the patient, from being tied to a house and home where he can move and perform the active life that the patient had, perhaps before the accident, or what it is that has put the patient in this situation. A short summary of what Integrum does. Nu drar vi en uppdatering av vårt andra kvartal. Vi har brutit räkenskapsår. Detta är vårt verksamhets...